New pill targets gene flaws in hard-to-treat bile duct cancer
NCT ID NCT06777316
First seen Apr 18, 2026 · Last updated Jun 16, 2026 · Updated 10 times
Summary
This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tried standard treatments will take the pill, and researchers will monitor safety, side effects, and how well it shrinks or controls the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fox Chase cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Huntsman Cancer Institute - University of Utah
Salt Lake City, Utah, 84112, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Princess Margaret Cancer Centre - UHN
Toronto, Ontario, M5G 2C4, Canada
-
Stanford Cancer Institute
Palo Alto, California, 94305, United States
-
Taussig Cancer Center - Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
The Christ Hospital
Cincinnati, Ohio, 45219, United States
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.